G

ood morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember, there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Our flavor today is mocha nut fudge. Remember that no prescription is required. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day and please do stay in touch …

Novartis recently discovered a drug it sells for rare inflammatory disorders could be used to treat a more common ailment, but there’s a problem: the $16,000-per-dose price tag, The Wall Street Journal says. Sold as Ilaris, a recent clinical trial suggests it can reduce the risk of serious complications in heart attack patients. But if it wins regulatory approval, Novartis would have to drastically cut its price to make it competitive with other cardiovascular drugs.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • If I were consulting Novartis I would urge them to do a head to head comparison trial on Ilaris up and running ASAP. If the NVS drug shows superiority then go ahead and charge their $16,000 per dose

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.